medigraphic.com
ISSN 2954-3835 (Electronic)
ISSN 2683-2828 (Print)

2020, Number S3

<< Back Next >>

Cardiovasc Metab Sci 2020; 31 (S3)

Recommendations for the care of patients with heart failure and COVID-19

Cigarroa-López JA, Magaña-Serrano JA, Álvarez-Sangabriel A, Ruíz-Ruíz V, Chávez-Mendoza A, Méndez-Ortíz A, León-González S, Guízar-Sánchez C, Gutiérrez-Fajardo P, Alcocer-Gamba MA

Language: Spanish
References: 22
Page: 190-196
PDF size: 243.46 Kb.


ABSTRACT

The COVID-19 pandemic decreed by the World Health Organization (WHO) since March 12, 2020 is wreaking havoc globally and it is a true economic, social and health challenge. Although the clinical manifestations of COVID-19 are respiratory symptoms, some patients also have cardiological symptoms. Among patients with cardiological conditions they represent a group of higher risk and, in fact, they are a particularly vulnerable group, due to their higher risk of contagion and greater severity in case of acquiring the disease those with heart failure (HF), including heart transplant (CT) and ventricular assists, as well as patients with pulmonary arterial hypertension (PAH). HF is the main chronic cardiovascular disease and patients in this group are the most vulnerable for the development of more serious clinical symptoms after suffering the infection, and to a greater extent cases with advanced HF. In fact, HF is one of the most frequent complications in patients with COVID-19. Likewise, transplant patients who require immunosuppressants to avoid graft rejection, constitute a population especially susceptible to infection and to develop more serious processes. This situation has made the National Association of Cardiologists of Mexico (ANCAM) and the Mexican Society of Cardiology (SMC) together with their respective chapters, have prepared the following recommendations for medical personnel, who participate in the care of this special group of patients in the different clinical settings, who suffer or not, of COVID-19.


REFERENCES

  1. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-513.

  2. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020; 323 (11): 1061-1069. doi: 10.1001/jama.2020.1585.

  3.  3. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17 (5): 259-260. doi: 10.1038/s41569-020-0360-5.

  4.  4. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 6736: 1-9. doi: 10.1016/S0140-6736(20)30566-3.

  5.  5. Bagudá JJ, Farrero TM, Recio MA, García-Cosío MD et al. Implicaciones de la pandemia por COVID-19 para el paciente con insuficiencia cardiaca, trasplante cardiaco y asistencia ventricular. Recomendaciones de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología. 2020. Disponible en: https://secardiologia.es/images/secciones/insuficiencia/Implicaciones_de_la_pandemia_por_COVID-19_para_el_paciente_con_insuficiencia_cardiaca_trasplante_cardiaco_y_asistencia_ventricular.pdf

  6.  6. Recomendaciones al Subsistema Nacional de Donación y Trasplantes sobre la Infección Asociada al SARS-CoV-2 (COVID-19). [publicada el 1 de abril de 2020] www.gob.mx/cenatra.

  7.  7. Torres A, Rivera A, García A et al. Evaluación y tratamiento de la insuficiencia cardiaca durante la pandemia de COVID-19: resumen ejecutivo. Recomendaciones del capítulo de falla cardiaca, trasplante e hipertensión pulmonar de la Asociación Colombiana de Cardiología y Cirugía Cardiovascular. Marzo 2020.

  8.  8. Krahn A, Bewick SJ, Chow Ch et al. Guidance from the CCS COVID-19 rapid response team. Canadian Cardiovascular Society. Marzo 2020.

  9.  9. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hyper- tension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37 (1): 67-119.

  10. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE et al. Predicting survival in patients with pulmonary arterial hypertension: the reveal risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019; 156 (2): 323-337.

  11. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36 (3): 549-555.

  12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506.

  13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-1720.

  14. Price LC, Wort SJ. Pulmonary hypertension in ARDS: inflammation matters! Thorax. 2017; 72 (5): 396-397.

  15. Pandolfi R, Barreira B, Moreno E, Lara-Acedo V, Morales-Cano D, Martínez-Ramas A et al. Role of acid sphingomyelinase and IL-6 as media- tors of endotoxin-induced pulmonary vascular dysfunction. Thorax. 2017; 72 (5): 460-471.

  16. Pan IZ, Carey JR, Jacobs JA et al. Transitioning between prostanoid therapies in pulmonary arterial hypertension. Front Med (Lausanne). 2020; 7: 81.

  17. — Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019; 53 (1): 1801906.

  18. — https://www.who.int/publications-detail/clinical-management-of-seve- re-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection- is-suspected

  19. — Padang R, Chandrashekar N, Indrabhinduwat M, Scott CG, Luis SA, Chandrasekaran K et al. Aetiology and outcomes of severe right ventricular dysfunction. Eur Heart J. 2020; 41 (12): 1273-1282.

  20. — Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D et al. Outcomes of hospitalization for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011; 38 (2): 359-367.

  21. — Wang D, Li S, Jiang J, Yan J, Zhao C, Wang Y et al. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci. 2019; 62 (2): 187-202. doi: 10.1007/s11427-018-9385-3.

  22. — Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J. 2016 Dec 30;:]. Eur Heart J. 2016; 37 (27): 2129-2200. doi: 10.1093/eurheartj/ehw128.




2020     |     www.medigraphic.com